Contents

Molecular Cancer Therapeutics
The Cancer Drug Development Journal: From Concept to Clinic
June 2012 • Volume 11 • Number 6

CORRECTION

ABOUT THE COVER

The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes *in vitro* via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1^{+}, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1^{-}. This strongly suggests that CEACAM1-mediated inhibition occurs *in vivo* and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300.



Molecular Cancer Therapeutics

11 (6)

Mol Cancer Ther 2012;11:1219-1381.